New study to uncover hidden heart risks of hormone therapy in transgender individuals

NCT ID NCT07394400

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study will follow 94 transgender individuals for 12 months to see how gender-affirming hormone therapy affects their mood, stress, and heart health. Researchers will measure inflammation, blood vessel function, and other markers to understand potential cardiovascular risks. The goal is to improve healthcare for transgender people by providing clearer information on the benefits and risks of hormone therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

gender-affirming hormone therapy

What this could lead to

If successful, this study could help doctors better understand the risks and benefits of hormone therapy for transgender individuals, leading to safer and more personalized care.

What could go wrong

This is an observational study, not a treatment trial. It will not prove cause and effect, and results may take years to influence medical guidelines.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSGENDER INDIVIDUALS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis Inflammation periodontal disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital Universitario Doctor Peset

    Valencia, Valencia, 46017, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••